Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]-Labelled Nebicapone in Healthy Male Subjects
NCT02772614Phase 1Completed
- Sponsor
- BIAL
- Start
- Jan 2006
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nebicapone in Parkinson's disease (PD), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration at 264 hours, Time of Occurrence of Cmax at 264 hours and 2 more. Started Jan 2006; status: completed.
02
Drugs
nebicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02772614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772614.